← Back to Search

Monoclonal Antibodies

Zanidatamab vs Trastuzumab for Breast Cancer

Phase 3
Recruiting
Research Sponsored by Jazz Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has histologically confirmed HER2-positive breast cancer according to ASCO-CAP Guidelines as evaluated by a central laboratory
Participants with unresectable or metastatic HER2 positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up until death, up to approximately 80 months
Awards & highlights

Summary

This trial will test a new drug called zanidatamab in combination with chemotherapy to see if it is better than the current standard treatment using trastuzumab and chemotherapy for patients with

Who is the study for?
This trial is for adults with HER2-positive breast cancer that's spread and who've had issues with a previous treatment called T-DXd. They need to have measurable cancer growth, be expected to live at least 6 more months, and their body functions (like blood cells, liver, kidneys) must meet certain levels.
What is being tested?
The study compares Zanidatamab plus a chemotherapy chosen by the doctor against Trastuzumab with the same chemo options. It aims to see which combination is safer and works better for patients whose cancer has worsened after T-DXd treatment.
What are the potential side effects?
Possible side effects include reactions related to infusion of the drugs, impact on organ function like heart or lungs from Zanidatamab or Trastuzumab, as well as typical chemo side effects such as nausea, fatigue, low blood counts leading to increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breast cancer is HER2-positive, confirmed by a specialized lab.
Select...
My HER2 positive breast cancer cannot be surgically removed and has worsened despite previous treatment.
Select...
I can be treated with eribulin, gemcitabine, vinorelbine, or capecitabine.
Select...
My kidneys are functioning well enough, with a creatinine clearance rate of 30 mL/min or higher.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~until death, up to approximately 80 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and until death, up to approximately 80 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)
Secondary outcome measures
Confirmed ORR Per RECIST Version 1.1, As Assessed By Investigator
Confirmed Objective Response Rate (ORR) Per RECIST Version 1.1, As Assessed by BICR
DOR Per RECIST Version 1.1, As Assessed By Investigator
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Zanidatamab plus physician's choice of chemotherapyExperimental Treatment5 Interventions
Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of zanidatamab plus physician's choice of chemotherapy (eribulin, or vinorelbine, or gemcitabine, or capecitabine).
Group II: Trastuzumab plus physician's choice of chemotherapyActive Control5 Interventions
Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of trastuzumab plus physician's choice of chemotherapy (eribulin, or gemcitabine, or vinorelbine, or capecitabine).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Eribulin
2012
Completed Phase 3
~2740
Vinorelbine
2013
Completed Phase 4
~2190
Gemcitabine
2017
Completed Phase 3
~1920
Capecitabine
2013
Completed Phase 3
~3970

Find a Location

Who is running the clinical trial?

Jazz PharmaceuticalsLead Sponsor
249 Previous Clinical Trials
34,385 Total Patients Enrolled
~367 spots leftby Sep 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top